PROBLEM TO BE SOLVED: To provide a composition and a method which are useful for utilizing antitumor property of an anti-CS1 antibody.SOLUTION: A pharmaceutical composition contains an antibody (HuLuc63) specific for CS1 (CD2 subset 1), which is a member of a CD2 family of cell surface glycoprotein and highly expressed in a myeloma cell, in combination with one or more therapeutic agents. A method for treating multiple myeloma by using the composition. An administration method in which one or more therapeutic agents such as targeting medicine, customary chemotherapeutic agent, hormone therapeutic agent and an auxiliary care substance and/or a combination thereof can be administered simultaneous with administration of an anti-CS1 antibody, before administration of an anti-CS1 antibody, or subsequent to administration of an anti-CS1 antibody. A pharmaceutical composition in which the chemotherapeutic agent is selected from thalidomide, vincristine, cisplatin, melphalan or the like, the hormone therapeutic agent is selected from dexamethasone or prednisone, and the composition preferably contains dexamethasone and thalidomide.SELECTED DRAWING: Figure 1【課題】抗ＣＳ１抗体の抗腫瘍特性を活用するのに有用な組成物及び方法の提供。【解決手段】骨髄腫細胞において高度に発現される、細胞表面糖タンパク質のＣＤ２ファミリーのメンバーであるＣＳ１（ＣＤ２サブセット１）に特異的な抗体（ＨｕＬｕｃ６３）を、１以上の治療剤と組み合わせて含む医薬組成物。該組成物を使用して多発性骨髄腫を処置する方法。標的化薬剤、慣習的な化学療法剤、ホルモン治療剤および補助ケア物質および／またはそれらの組み合わせのような１以上の治療剤が、抗ＣＳ１抗体の投与と同時に、抗ＣＳ１抗体の投与より前に、または抗ＣＳ１抗体の投与に続いて、投与され得る投与方法。前記化学療法剤がサリドマイド、ビンクリスチン、シスプラチン、メルファラン等から選択され、前記ホルモン治療剤がデキサメタゾン又はプレドニゾンから選択され、好ましくはデキサメタゾン及びサリドマイドを含む医薬組成物。【選択図】図１
